Results 231 to 240 of about 134,360 (302)

Cardiovascular Outcomes in a SELECT‐Like Obesity Cohort: Real‐World Insights From the Swedish AROS Database

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background In the SELECT trial, semaglutide reduced major adverse cardiovascular outcomes (MACE) in individuals with overweight or obesity and established cardiovascular disease (CVD) but without diabetes. However, real‐world cardiovascular event rates in comparable populations remain uncharacterised.
Viveca Ritsinger   +5 more
wiley   +1 more source

Trends in Potentially Avoidable Hospitalisations Among People With Diabetes in Ireland; 2015–2024

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To examine trends in potentially avoidable hospitalisations (PAHs) among people with diabetes in Ireland between 2015 and 2024, and how trends differ by sex and diabetes type. Material and Methods Using national hospitalisation data from the Republic of Ireland, we estimated rates and trends in PAHs among people with diagnosed type 1 or ...
Jennifer A. Pallin   +8 more
wiley   +1 more source

Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Empagliflozin is renoprotective in Type 2 diabetes mellitus (T2DM). Our primary aim was to assess empagliflozin's effect on glomerular filtration rate and renal vascular resistance using multiparametric MRI (MpMRI). Our secondary aim was to assess the impact of empagliflozin on additional MpMRI‐derived metrics including markers of tissue ...
Ruth P. Lim   +9 more
wiley   +1 more source

Intraoperative Traction for Cephalomedullary Nailing in Amputation Patients. [PDF]

open access: yesJ Orthop Case Rep
Runge NE   +3 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy